BR112012015852B8 - anticorpo do receptor da prolactina, sequência de ácido nucleico isolada, vetor de expressão,microrganismo transgênico, método de produzir,composição farmacêutica e kit - Google Patents
anticorpo do receptor da prolactina, sequência de ácido nucleico isolada, vetor de expressão,microrganismo transgênico, método de produzir,composição farmacêutica e kitInfo
- Publication number
- BR112012015852B8 BR112012015852B8 BR112012015852A BR112012015852A BR112012015852B8 BR 112012015852 B8 BR112012015852 B8 BR 112012015852B8 BR 112012015852 A BR112012015852 A BR 112012015852A BR 112012015852 A BR112012015852 A BR 112012015852A BR 112012015852 B8 BR112012015852 B8 BR 112012015852B8
- Authority
- BR
- Brazil
- Prior art keywords
- prolactin receptor
- kit
- nucleic acid
- acid sequence
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075546A EP2332995A1 (en) | 2009-12-10 | 2009-12-10 | Neutralizing prolactin receptor antibodies and their therapeutic use |
| EP09075546.3 | 2009-12-10 | ||
| PCT/EP2010/067742 WO2011069795A1 (en) | 2009-12-10 | 2010-11-18 | Neutralizing prolactin receptor antibodies and their therapeutic use |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR112012015852A2 BR112012015852A2 (pt) | 2017-05-23 |
| BR112012015852A8 BR112012015852A8 (pt) | 2017-06-27 |
| BR112012015852B1 BR112012015852B1 (pt) | 2020-12-29 |
| BR112012015852B8 true BR112012015852B8 (pt) | 2021-05-25 |
Family
ID=42091520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012015852A BR112012015852B8 (pt) | 2009-12-10 | 2010-11-18 | anticorpo do receptor da prolactina, sequência de ácido nucleico isolada, vetor de expressão,microrganismo transgênico, método de produzir,composição farmacêutica e kit |
| BR112012014048-5A BR112012014048B1 (pt) | 2009-12-10 | 2010-11-18 | Anticorpos de receptor de prolactina ou fragmentos de ligação de antígenos, seus usos, sequência de ácido nucléico, vetor de expressão, bem como célula hospedeira e seu uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012014048-5A BR112012014048B1 (pt) | 2009-12-10 | 2010-11-18 | Anticorpos de receptor de prolactina ou fragmentos de ligação de antígenos, seus usos, sequência de ácido nucléico, vetor de expressão, bem como célula hospedeira e seu uso |
Country Status (40)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| HUE047173T2 (hu) | 2010-03-01 | 2020-04-28 | Bayer Healthcare Llc | Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| MX361875B (es) | 2012-03-14 | 2018-12-18 | Regeneron Pharma | Moléculas de unión de antígeno multiespecifícas y usos de las mismas. |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| CN105102480B (zh) * | 2012-12-24 | 2019-04-16 | 艾伯维公司 | 催乳素受体结合蛋白及其用途 |
| EP2968538A1 (en) * | 2013-03-15 | 2016-01-20 | Bayer HealthCare LLC | Anti-prolactin receptor antibody formulations |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| US10308697B2 (en) | 2014-04-30 | 2019-06-04 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
| CN117442748A (zh) | 2014-10-02 | 2024-01-26 | 希望之城公司 | 多价中间表位、中间表位结合抗体及其用途 |
| BR112017015661A2 (pt) | 2015-01-30 | 2018-03-20 | Saitama Medical University | anticorpo anti-alk2 |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| WO2018102304A1 (en) | 2016-11-29 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| FR3062213B1 (fr) * | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| US11202776B2 (en) * | 2017-05-12 | 2021-12-21 | Takeda Pharmaceutical Company Limited | Treatment of gastroparesis with triazaspiro[4.5]decanone |
| PE20200481A1 (es) | 2017-07-10 | 2020-03-03 | Bayer Pharma AG | Anticuerpo del receptor de prolactina para la perdida de cabello con patrones masculinos y femeninos |
| JP7779653B2 (ja) | 2018-02-07 | 2025-12-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療用タンパク質送達のための方法および組成物 |
| WO2019169330A1 (en) * | 2018-03-02 | 2019-09-06 | Oncolix, Inc. | Method for treating cancers expressing prolactin receptor |
| CN109627340B (zh) * | 2018-12-05 | 2021-02-12 | 上海交通大学 | Cd3和prlr双特异性抗体及其构建与应用 |
| US10467487B1 (en) * | 2018-12-11 | 2019-11-05 | Chongqing Jinkang New Energy Automobile Co., Ltd. | Fusion-based traffic light recognition for autonomous driving |
| CN112425568A (zh) * | 2020-12-11 | 2021-03-02 | 上海市计划生育科学研究所 | 一种建立具有emt特征的良性前列腺增生bph犬模型的方法 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN114853890B (zh) * | 2022-03-16 | 2023-04-28 | 沈阳三生制药有限责任公司 | 一种prlr抗原结合蛋白及其制备方法和应用 |
| CN114634574B (zh) * | 2022-04-18 | 2022-12-20 | 先进生物(苏州)有限公司 | 抗B7H6的scFv抗体、其编码基因及其应用 |
| CN120842400A (zh) * | 2023-04-24 | 2025-10-28 | 深圳真实生物医药科技有限公司 | 泌乳素受体抗体及其用途 |
| CN117285625B (zh) * | 2023-11-24 | 2024-01-23 | 南京佰抗生物科技有限公司 | 抗泌乳素蛋白的单克隆抗体及应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4986615A (en) | 1988-10-17 | 1991-01-22 | The Vendo Company | Vending apparatus |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| GB9105245D0 (en) * | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| WO1998010765A1 (en) * | 1996-09-13 | 1998-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Non-hormonal method of contraception |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US6867187B2 (en) * | 2000-12-22 | 2005-03-15 | Trustees Of The University Of Pennsylvania | Composition and method for modulating somatolactogenic function |
| EP1325930A1 (en) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
| CA2509825A1 (en) * | 2002-12-13 | 2004-07-01 | The Ohio State University | Antagonists for human prolactin |
| GB0305790D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Novel Composition |
| CA2585977C (en) * | 2004-10-28 | 2013-07-02 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for endometriosis |
| WO2006089678A2 (en) * | 2005-02-22 | 2006-08-31 | Bioinvent International Ab | Antibodies and peptides binding to hiv tat, and uses thereof |
| GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| AR062435A1 (es) * | 2006-08-18 | 2008-11-05 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
| CN102711773A (zh) | 2007-05-30 | 2012-10-03 | 奥克兰联合服务有限公司 | 生长激素和相关激素的抑制剂,和其使用方法 |
| EP2025683A1 (en) * | 2007-08-13 | 2009-02-18 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Variants of prolactin as antagonists of its receptor |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| WO2011139375A1 (en) * | 2010-05-06 | 2011-11-10 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against carbonic anhydrase ix and methods and uses thereof |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
-
2009
- 2009-12-10 EP EP09075546A patent/EP2332995A1/en not_active Withdrawn
-
2010
- 2010-11-18 AU AU2010330161A patent/AU2010330161B2/en active Active
- 2010-11-18 MA MA34951A patent/MA33888B1/fr unknown
- 2010-11-18 WO PCT/EP2010/067747 patent/WO2011069799A1/en not_active Ceased
- 2010-11-18 NZ NZ600511A patent/NZ600511A/en unknown
- 2010-11-18 WO PCT/EP2010/067746 patent/WO2011069798A1/en not_active Ceased
- 2010-11-18 CA CA2783513A patent/CA2783513C/en active Active
- 2010-11-18 HU HUE10776753A patent/HUE031631T2/en unknown
- 2010-11-18 CN CN2010800634488A patent/CN102858803A/zh active Pending
- 2010-11-18 HR HRP20170016TT patent/HRP20170016T1/hr unknown
- 2010-11-18 PE PE2017000782A patent/PE20171134A1/es unknown
- 2010-11-18 SI SI201031367A patent/SI2510006T1/sl unknown
- 2010-11-18 WO PCT/EP2010/067742 patent/WO2011069795A1/en not_active Ceased
- 2010-11-18 EP EP12192721A patent/EP2570436A1/en not_active Withdrawn
- 2010-11-18 DK DK10776753.5T patent/DK2510002T3/en active
- 2010-11-18 EP EP12192708A patent/EP2567979A1/en not_active Withdrawn
- 2010-11-18 RS RS20160915A patent/RS55277B1/sr unknown
- 2010-11-18 JP JP2012542435A patent/JP2013513364A/ja not_active Ceased
- 2010-11-18 US US13/514,996 patent/US9241989B2/en active Active
- 2010-11-18 JP JP2012542433A patent/JP2013513362A/ja active Pending
- 2010-11-18 AP AP2012006343A patent/AP2012006343A0/xx unknown
- 2010-11-18 US US13/514,992 patent/US9649374B2/en active Active
- 2010-11-18 PL PL10776753T patent/PL2510002T3/pl unknown
- 2010-11-18 WO PCT/EP2010/067740 patent/WO2011069794A1/en not_active Ceased
- 2010-11-18 EP EP12192707A patent/EP2570435A1/en not_active Withdrawn
- 2010-11-18 SI SI201031312A patent/SI2510002T1/sl unknown
- 2010-11-18 RS RS20170010A patent/RS55589B1/sr unknown
- 2010-11-18 EP EP10781671A patent/EP2510004A1/en not_active Withdrawn
- 2010-11-18 CN CN201080063268XA patent/CN102858801A/zh active Pending
- 2010-11-18 EP EP12192705A patent/EP2567978A1/en not_active Withdrawn
- 2010-11-18 EP EP10782255.3A patent/EP2510006B1/en active Active
- 2010-11-18 NZ NZ600512A patent/NZ600512A/en unknown
- 2010-11-18 EP EP10784482A patent/EP2510007A1/en not_active Withdrawn
- 2010-11-18 US US13/514,994 patent/US20120315276A1/en not_active Abandoned
- 2010-11-18 EA EA201200860A patent/EA028678B1/ru not_active IP Right Cessation
- 2010-11-18 EP EP12192722A patent/EP2567980A1/en not_active Withdrawn
- 2010-11-18 CN CN2010800634492A patent/CN102858804A/zh active Pending
- 2010-11-18 US US13/514,995 patent/US20130022606A1/en not_active Abandoned
- 2010-11-18 PE PE2012000791A patent/PE20121360A1/es not_active Application Discontinuation
- 2010-11-18 CN CN201080063347.0A patent/CN102947338B/zh active Active
- 2010-11-18 CA CA2783678A patent/CA2783678A1/en not_active Abandoned
- 2010-11-18 CA CA2783514A patent/CA2783514A1/en not_active Abandoned
- 2010-11-18 EP EP10779014A patent/EP2510003A1/en not_active Withdrawn
- 2010-11-18 BR BR112012015852A patent/BR112012015852B8/pt active IP Right Grant
- 2010-11-18 EA EA201200851A patent/EA029327B1/ru not_active IP Right Cessation
- 2010-11-18 CA CA2783610A patent/CA2783610C/en active Active
- 2010-11-18 EP EP12192704A patent/EP2567977A1/en not_active Withdrawn
- 2010-11-18 ES ES10776753.5T patent/ES2603352T3/es active Active
- 2010-11-18 PT PT107822553T patent/PT2510006T/pt unknown
- 2010-11-18 JP JP2012542432A patent/JP2013513361A/ja active Pending
- 2010-11-18 HR HRP20161401TT patent/HRP20161401T1/hr unknown
- 2010-11-18 IN IN5082DEN2012 patent/IN2012DN05082A/en unknown
- 2010-11-18 ES ES10782255.3T patent/ES2610654T3/es active Active
- 2010-11-18 CA CA2783654A patent/CA2783654A1/en not_active Abandoned
- 2010-11-18 LT LTEP10782255.3T patent/LT2510006T/lt unknown
- 2010-11-18 ME MEP-2016-244A patent/ME02577B/me unknown
- 2010-11-18 KR KR1020127017831A patent/KR101765968B1/ko active Active
- 2010-11-18 MX MX2012006621A patent/MX2012006621A/es unknown
- 2010-11-18 EP EP10776753.5A patent/EP2510002B1/en active Active
- 2010-11-18 WO PCT/EP2010/067743 patent/WO2011069796A1/en not_active Ceased
- 2010-11-18 LT LTEP10776753.5T patent/LT2510002T/lt unknown
- 2010-11-18 US US13/514,991 patent/US20120321632A1/en not_active Abandoned
- 2010-11-18 EP EP10781882A patent/EP2510005A1/en not_active Withdrawn
- 2010-11-18 JP JP2012542434A patent/JP2013513363A/ja active Pending
- 2010-11-18 JP JP2012542431A patent/JP2013513559A/ja active Pending
- 2010-11-18 JP JP2012542436A patent/JP6066474B2/ja active Active
- 2010-11-18 DK DK10782255.3T patent/DK2510006T3/en active
- 2010-11-18 MX MX2012006620A patent/MX339343B/es active IP Right Grant
- 2010-11-18 SG SG2012041166A patent/SG181511A1/en unknown
- 2010-11-18 AU AU2010330165A patent/AU2010330165B2/en active Active
- 2010-11-18 PH PH1/2012/501131A patent/PH12012501131A1/en unknown
- 2010-11-18 IN IN5078DEN2012 patent/IN2012DN05078A/en unknown
- 2010-11-18 SG SG2012041182A patent/SG181513A1/en unknown
- 2010-11-18 PL PL10782255T patent/PL2510006T3/pl unknown
- 2010-11-18 KR KR1020127017833A patent/KR101790366B1/ko active Active
- 2010-11-18 CA CA2783651A patent/CA2783651A1/en not_active Abandoned
- 2010-11-18 WO PCT/EP2010/067744 patent/WO2011069797A1/en not_active Ceased
- 2010-11-18 PH PH1/2012/501129A patent/PH12012501129A1/en unknown
- 2010-11-18 CN CN201080063269.4A patent/CN102884082B/zh active Active
- 2010-11-18 PE PE2012000797A patent/PE20121561A1/es not_active Application Discontinuation
- 2010-11-18 HU HUE10782255A patent/HUE030143T2/en unknown
- 2010-11-18 US US13/514,993 patent/US20130171147A1/en not_active Abandoned
- 2010-11-18 CN CN2010800633485A patent/CN102741291A/zh active Pending
- 2010-11-18 PT PT107767535T patent/PT2510002T/pt unknown
- 2010-11-18 BR BR112012014048-5A patent/BR112012014048B1/pt active IP Right Grant
- 2010-12-10 AR ARP100104564A patent/AR079349A1/es unknown
- 2010-12-10 TW TW099143330A patent/TW201130506A/zh unknown
- 2010-12-10 AR ARP100104566A patent/AR079351A1/es unknown
- 2010-12-10 TW TW099143332A patent/TWI508744B/zh active
- 2010-12-10 AR ARP100104565A patent/AR079350A1/es unknown
- 2010-12-10 AR ARP100104563A patent/AR079348A1/es active IP Right Grant
- 2010-12-10 TW TW099143326A patent/TW201138817A/zh unknown
- 2010-12-10 AR ARP100104567A patent/AR079352A1/es active IP Right Grant
- 2010-12-10 TW TW099143328A patent/TWI487536B/zh active
- 2010-12-10 TW TW099143327A patent/TW201130504A/zh unknown
- 2010-12-17 AR ARP100104707A patent/AR079641A1/es unknown
-
2012
- 2012-06-04 IL IL220151A patent/IL220151A0/en active IP Right Grant
- 2012-06-04 IL IL220149A patent/IL220149A/en active IP Right Grant
- 2012-06-07 CU CU2012000093A patent/CU23973B1/es not_active IP Right Cessation
- 2012-06-07 CU CU2012000092A patent/CU20120092A7/es unknown
- 2012-06-08 ZA ZA2012/04214A patent/ZA201204214B/en unknown
- 2012-06-08 CL CL2012001540A patent/CL2012001540A1/es unknown
- 2012-06-08 ZA ZA2012/04213A patent/ZA201204213B/en unknown
- 2012-06-08 EC ECSP12011965 patent/ECSP12011965A/es unknown
- 2012-06-08 GT GT201200186A patent/GT201200186A/es unknown
- 2012-06-08 CR CR20120310A patent/CR20120310A/es unknown
- 2012-06-08 CL CL2012001539A patent/CL2012001539A1/es unknown
- 2012-06-08 EC ECSP12011966 patent/ECSP12011966A/es unknown
- 2012-06-08 DO DO2012000160A patent/DOP2012000160A/es unknown
- 2012-06-08 TN TNP2012000294A patent/TN2012000294A1/en unknown
- 2012-06-08 CR CR20120312A patent/CR20120312A/es unknown
- 2012-06-08 DO DO2012000159A patent/DOP2012000159A/es unknown
-
2015
- 2015-07-03 JP JP2015134286A patent/JP6199930B2/ja active Active
-
2016
- 2016-10-31 CY CY20161101101T patent/CY1118209T1/el unknown
-
2017
- 2017-01-10 CY CY20171100030T patent/CY1118407T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012015852B8 (pt) | anticorpo do receptor da prolactina, sequência de ácido nucleico isolada, vetor de expressão,microrganismo transgênico, método de produzir,composição farmacêutica e kit | |
| BR112013030995A2 (pt) | "anticorpo mat3 ou fragmentos de ligação antigênica do mesmo e seus usos, sequência de ácido nucleico isolada, vetor de expressão, célula hospedeira e seu método de uso, composição farmacêutica, e kits". | |
| MX2019005911A (es) | Anticuerpos anti_cd137 novedosos y usos de estos. | |
| CY1119661T1 (el) | 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγα, μεθοδοι για την παραγωγη αυτων και χρηση αυτων για την αγωγη παθησεων | |
| EA201171374A1 (ru) | Антитела против cd100 и способы их применения | |
| MX369148B (es) | Agentes de unión kir3dl2. | |
| EA201491096A1 (ru) | Производные 6,7-дигидро-5h-бензо[7]аннулена, способ их получения, фармацевтические препараты, которые их содержат, а также их применение для изготовления лекарственных средств | |
| MX2017011600A (es) | Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. | |
| EA201491344A1 (ru) | Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона | |
| JP2016523558A5 (https=) | ||
| EA201792524A1 (ru) | Режим приема селективного модулятора рецептора прогестерона (sprm) | |
| EA201690309A1 (ru) | Бивалентные вакцинные композиции и их применение для лечения опухолей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25G | Requested change of headquarter approved |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE) |